Phase 3 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with endometrial carcinoma (uterine cancer) or carcinosarcoma, confirmed by a lab test on a tissue sample.
- Your cancer has come back or spread to other parts of the body, with evidence shown on scans or other objective tests.
- You have previously received platinum-based chemotherapy and immunotherapy (a type of treatment that targets PD-1 or PD-L1), whether given separately or together.
- You are generally well enough to carry out light activity and care for yourself (a doctor will assess this using a standard scale).
- Your cancer can be measured on a scan using standard medical guidelines.
Who may not be able to join:
- You have been diagnosed with uterine sarcoma or uterine neuroendocrine carcinoma (specific types of uterine cancer that are different from endometrial carcinoma).
- Your cancer came back more than 12 months after finishing platinum-based chemotherapy given with the aim of curing you, and you have not had any further platinum-based treatment since then.
- You have previously received any treatment — approved or experimental — that included a specific type of drug called a TOP1 inhibitor, including a type of targeted drug delivery called an antibody-drug conjugate (confirm with trial site).
- You have previously been treated with Puxi-Sam or any other drug that targets a protein called B7-H4.
- You have a history of, or currently have, a lung condition involving inflammation or scarring (not caused by infection) that required steroid treatment, or a similar lung condition cannot be ruled out by your screening scans.
- You have serious breathing difficulties caused by a lung illness.
- You have an active or previously diagnosed condition where your immune system attacks your own body (an autoimmune or inflammatory disorder).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Brian Slomovitz, MD, Icahn School of Medicine at Mount Sinai
Phone: 1-877-240-9479
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression Free Survival (PFS) for Arm A vs Arm B; Overall survival (OS) for Arm A vs Arm B
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.